Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

Engaging all stakeholders in the process of establishing a global MI service is key to its overall success. Each ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

Sidders discusses how integrating causality in AI for biotechnology can drive greater R&D success, and more generally about ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

The Market Access for CNS Therapeutics Summit is the only dedicated forum focused on tackling the unique commercial and ...